Active	Status	Sponsor type	Region	Phase	Filter
25 Active 9 Inactive 34 All	Not yet recruiting Recruiting Enrolling by invitation Active, not recruiting Available No longer recruiting	Industry lead sponsor Industry collaborator Coop Other	US Canada Japan Europe RoW	N/A 1 2 3 4	Highlight changes:- Show only changed items Enrollment:

Advanced Filters

7 Trials

Active Trials   Industry lead sponsorIndustry collaborator

 

Export

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
Liu, Lin
NCT05003245: Compare the Efficacy and Safety of HLX04-O With Ranibizumab in Subjects With wAMD	Recruiting	3	388	RoW	HLX04-O，recombinant anti-vascular endothelial growth factor (VEGF) humanized monoclonal antibody ophthalmic injection, Lucentis	Shanghai Henlius Biotech	Age Related Macular Degeneration	08/23	03/24
NCT04586478: Phase II Clinical Trial of CNCT19 Cell Injection in the Treatment of Relapsed or Refractory Non-Hodgkin's Lymphoma	Recruiting	2	60	RoW	single dose of CNCT19	Juventas Cell Therapy Ltd.	Non-Hodgkin's Lymphoma	12/24	09/25
NCT05688696: Evaluate the Efficacy and Safety of Orelabrutinib in Adult Patients With Systemic Lupus Erythematosus	Recruiting	2	186	RoW	Orelabrutinib (Low Dose), Orelabrutinib (High Dose), Orelabrutinib Placebo	Beijing InnoCare Pharma Tech Co., Ltd.	Systemic Lupus Erythematosus, SLE	08/25	05/26
NCT06387082: A Clinical Study of HMPL-506 in Patients With Hematological Malignancies	Recruiting	1	98	RoW	HMPL-506, Two strengths of HMPL-506 tablets (25 mg and 100 mg) will be used for this clinical study	Hutchmed	Hematological Malignancies	10/27	12/27
NCT04606433: Phase I Clinical Study of GNC-038 in Patients With Non-Hodgkin's Lymphoma or Acute Lymphoblastic Leukemia	Recruiting	1	41	RoW	GNC-038	Sichuan Baili Pharmaceutical Co., Ltd., SystImmune Inc.	Non Hodgkin Lymphoma, Acute Lymphoblastic Leukemia	06/25	11/25
Li, Wen
NCT05042375: A Trial of Camrelizumab Combined With Famitinib Malate in Treatment Naïve Subjects With PD-L1-Positive Recurrent or Metastatic Non-Small Cell Lung Cancer	Recruiting	3	450	RoW	camrelizumab + famitinib, pembrolizumab, camrelizumab	Jiangsu HengRui Medicine Co., Ltd.	Non-small Cell Lung Cancer	12/23	12/25
PRESERVE-003, NCT05671510: ONC-392 Versus Docetaxel in Metastatic NSCLC That Progressed on PD-1/PD-L1 Inhibitors	Active, not recruiting	3	600	Europe, Canada, US, RoW	Gotistobart, A humanized anti-CTLA4 IgG1 monoclonal antibody, ONC-392, BNT316, Docetaxel, Docefrez, Taxotere	OncoC4, Inc., BioNTech SE	Non Small Cell Lung Cancer	06/26	06/27
Zhan, Shao-feng
No trials found